Tracy Thompson

Tracy Thompson leads Helogen's Life Sciences division, focusing on developing autonomous biological research satellites in low Earth orbit. With over 40 years of experience spanning product development, corporate leadership, and scientific innovation, Tracy brings a broad perspective to advancing space-based biology. Prior to Helogen, he founded two companies specializing in bionanoparticle technologies. His work includes developing diagnostics that differentiate infected from vaccinated animals and creating nanoparticles for cancer immunotherapies that mimic viruses to target tumors. A recognized expert in biotechnology, Tracy has spoken at the BIO International Convention and other global conferences, delivering keynote addresses on affinity chromatography and bioprocessing. His expertise has also extended to advising the New Zealand government on science and technology priorities, managing national research investments. Currently, Tracy's team is developing compact, 3-liter autonomous satellite laboratories capable of performing complex biological experiments in orbit-similar to those on Earth or the ISS. These labs utilize validated sensors for rapid, client-specific research, building on his early work in automated point-of-care diagnostics. Tracy holds a Bachelor's degree in Biochemistry from San Jose State University and studied pharmaceutical chemistry at UC San Francisco. Despite his diverse background, he humbly describes himself as, "œjust a guy".



Helogen Corporation
Thursday
May 08
Space Therapies: Accelerating Biotech Solutions for Health Beyond Earth
2:30 PM

-

3:15 PM

Space is among the harshest and least hospitable environments for humans. Every human biological system is affected by the space environment. The biological stress has a deleterious impact on health and physical capabilities, and the extreme conditions and isolation take a significant toll on mental performance and behavior. By 2040, hundreds of people will be in space at any given time, and more than 80% of those are predicted to be private citizens; for the reliability, safety, health, and enjoyment of those private participants, new solutions and therapeutics are needed to maintain health and wellbeing.

Other Speakers

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025